References
Keating GM, Jarvis B. Management of rheumatoid arthritis: defining the role of etanercept. Dis Manage Health Outcomes 2002; 10(1): 17–39
Jarvis B, Faulds D. Etanercept. A review of its use in rheumatoid arthritis. Drugs 1999 Jun; 57(6): 945–66
Wolfe F, Cush JJ, O’Dell JR, et al. Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol 2001 Jun; 28: 1423–30
Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000 Jun; 59(6): 1341–59
Richard-Miceli C, Dougados M. Tumour necrosis factorα blockers in rheumatoid arthritis. BioDrugs 2001; 15(4): 251–59
British National Formulary. No 42. London: The Pharmaceutical Press, 2001 Sep: 485
Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor amonoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932–9
Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93
Spencer-Green G, Genovese M, Martin RW, et al. Etanercept versus methotrexate in early rheumatoid arthritis (ERA trial): two-year follow-up [abstract]. J Rheumatol 2001 Jul; 28 Suppl. 63: 106
Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized controlled study. Arch Intern Med 1999; 130: 478–86
Weinblatt ME, Kremer JM, Bankhurst, AD, et al. A trial of etanercept, a recombinant tumour necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9
Jones M, Symmons D, Finn J, et al. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996; 35: 738–45
Infliximab (Remicade®): prescribing information. Malvern (PA): Centocor, 1999.
Smolen JS, Steiner G, Breedveld FC, et al. Anti-TNFα therapy and drug-induced lupus-like syndrome [abstract no. 906]. Ann Rheum Dis 1999 Jun 6; EULAR Suppl.: 217
Emery P, Reginster JY, Appelboom T, et al. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 699–702
Rights and permissions
About this article
Cite this article
Tumour necrosis factor-α blockers: increasing the options for managing rheumatoid arthritis. Drugs Ther. Perspect 18, 16–20 (2002). https://doi.org/10.2165/00042310-200218050-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200218050-00006